Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute for Clinical Genetics, |
RCV003238357 | SCV002009147 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001762614 | SCV002416903 | likely benign | Familial cancer of breast | 2024-12-10 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV001357566 | SCV001553072 | uncertain significance | Malignant tumor of breast | no assertion criteria provided | clinical testing | The BARD1 c.1904-12T>G variant was not identified in the literature nor was it identified in the ClinVar, Cosmic, or Zhejiang University databases. The variant was identified in dbSNP (ID: rs774178253). The variant was identified in control databases in 1 of 120770 chromosomes at a frequency of 0. 000008 (Exome Aggregation Consortium, August 8th 2016), specifically in the European population in 1 of 66366 chromosomes (freq: 0. 00002), while the variant was not observed in the African, Other, Latino, Ashkenazi Jewish, East Asian, Finnish, or South Asian populations. The c.1904-12T>G variant is located in the 3' splice region but does not affect the invariant -1 and -2 positions. However, positions -3 and -5 to -12 are part of the splicing consensus sequence and variants involving these positions sometimes affect splicing. In addition, 3 of 4 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) predict a greater than 10% difference in splicing. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. |